Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Invested Capital (2017 - 2025)

Karyopharm Therapeutics' Return on Invested Capital history spans 9 years, with the latest figure at 0.16% for Q4 2025.

  • For Q4 2025, Return on Invested Capital fell 53.0% year-over-year to 0.16%; the TTM value through Dec 2025 reached 0.16%, down 53.0%, while the annual FY2025 figure was 0.18%, 56.0% down from the prior year.
  • Return on Invested Capital reached 0.16% in Q4 2025 per KPTI's latest filing, down from 0.43% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 4.49% in Q1 2023 to a low of 32.51% in Q1 2021.
  • Average Return on Invested Capital over 5 years is 0.49%, with a median of 0.86% recorded in 2024.
  • Peak YoY movement for Return on Invested Capital: plummeted -3092bps in 2021, then skyrocketed 3351bps in 2022.
  • A 5-year view of Return on Invested Capital shows it stood at 0.96% in 2021, then soared by 89bps to 1.82% in 2022, then crashed by -119bps to 0.34% in 2023, then soared by 305bps to 0.69% in 2024, then crashed by -77bps to 0.16% in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Return on Invested Capital are 0.16% (Q4 2025), 0.43% (Q3 2025), and 0.53% (Q2 2025).